Search results for "Kaplan-Meier"

showing 10 items of 359 documents

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial

2012

    In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30±5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in…

Graft RejectionCHRONIC KIDNEY-DISEASEMaleTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier EstimateLiver transplantationKidneyKidney Function TestsGLOMERULAR-FILTRATION-RATEImmunosuppressive AgentHEPATOCELLULAR-CARCINOMASIROLIMUS-BASED IMMUNOSUPPRESSIONImmunology and AllergySirolimuPharmacology (medical)Prospective StudiestacrolimusMYCOPHENOLATE-MOFETILCOMPLICATIONSCross-Over Studiesliver transplantationwithdrawalGraft SurvivalCross-Over StudieMiddle AgedTreatment Outcomesurgical procedures operativeSurvival AnalysireducedLife Sciences & BiomedicineImmunosuppressive AgentsHumanGlomerular Filtration Ratemedicine.drugAdultmedicine.medical_specialtyRandomizationTime FactorAdolescentEfficacyUrologyRenal functionchemical and pharmacologic phenomenaCALCINEURIN INHIBITORRisk AssessmentDrug Administration ScheduleFollow-Up StudieYoung Adultstomatognathic systemTransplantation ImmunologyDOSE TACROLIMUSConfidence IntervalsmedicineHumansMETAANALYSISAgedSirolimusTransplantationKidney Function TestScience & TechnologyEverolimusDose-Response Relationship Drugbusiness.industryeverolimutacrolimuOriginal ArticleseverolimusSurvival AnalysisCrossover studyTacrolimusSurgeryTransplantationProspective StudieCONVERSIONstomatognathic diseasesSirolimusSurgerybusinessConfidence IntervalLiver FailureFollow-Up StudiesAmerican Journal of Transplantation
researchProduct

Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation

2013

Introduction. Combined liver-kidney transplantation (LKT) is the best therapeutic option for patients with end-stage liver and kidney disease. Objectives. To analyze baseline characteristics and clinical outcome of LKT compared to isolated liver transplantation (LT). Material and methods. The study included 16 LKT performed between 1998 and 2006 and 32 LT matched by age, sex, date and indication for transplantation. Demographic, pretransplant, post-transplant and survival variables were analyzed. Results. As planned by the study design, mean age, distribution by sex and indication for LT were similar between groups. The most common indication for LT was HCV- and/or alcohol-induced cirrhosis…

Graft RejectionMaleTime FactorsCirrhosismedicine.medical_treatmentSpecialties of internal medicineKaplan-Meier EstimateLiver transplantationGastroenterologyKidney transplantationchemistry.chemical_compoundMetabolic complicationsRisk FactorsKidney transplantationOutcomeBacterial InfectionsGeneral MedicineMiddle AgedSurvival RateTreatment OutcomeRC581-951CreatinineHepatocellular carcinomaHypertensionFemaleAdultReoperationmedicine.medical_specialtyAdolescentPostoperative HemorrhageEnd Stage Liver DiseaseRenal DialysisDiabetes mellitusInternal medicinemedicineHumansArterial PressureDialysisAgedCreatinineChi-Square DistributionLiver transplantationHepatologyurogenital systembusiness.industrymedicine.diseaseSurgeryTransplantationchemistryCase-Control StudiesKidney Failure ChronicbusinessBiomarkers
researchProduct

Cumulative live-birth rates per total number of embryos needed to reach newborn in consecutive in vitro fertilization (IVF) cycles: a new approach to…

2011

Objective To report the use of cumulative live-birth rates (CLBRs) per ovarian stimulation cycle to measure the success of IVF is proving to be the most accurate method for advising couples who failed to conceive, although the accuracy yielded is relatively low, and cycle outcome is highly dependent on the number of embryos replaced. Our aim with this work is to report the CLBRs of IVF as a function of the number of embryos required to reach a live birth (EmbR), considering age, day of ET, and infertility etiology. Design Survival curves and Kaplan-Meier methods to analyze CLBR in a retrospective cohort with respect to the number of EmbR. Setting University-affiliated infertility center. Pa…

InfertilityAdultMalemedicine.medical_specialtymedicine.medical_treatmentFertilization in VitroKaplan-Meier EstimateBiologyIntracytoplasmic sperm injectionCohort StudiesPregnancymedicineHumansBirth RateSurvival analysisRetrospective StudiesGynecologyPregnancyIn vitro fertilisationInfant NewbornObstetrics and GynecologyRetrospective cohort studymedicine.diseaseEmbryo TransferReproductive MedicineFemaleLive birthLive BirthCohort studyFertility and sterility
researchProduct

Survival analysis of author keywords: An application to the library and information sciences area

2020

[EN] Our purpose is to adapt a statistical method for the analysis of discrete numerical series to the keywords appearing in scientific articles of a given area. As an example, we apply our methodological approach to the study of the keywords in the Library and Information Sciences (LIS) area. Our objective is to detect the new author keywords that appear in a fixed knowledge area in the period of 1 year in order to quantify the probabilities of survival for 10 years as a function of the impact of the journals where they appeared. Many of the new keywords appearing in the LIS field are ephemeral. Actually, more than half are never used again. In general, the terms most commonly used in the …

Information Systems and ManagementComputer Networks and CommunicationsKaplan-Meier05 social sciencesLibrary scienceBIBLIOTECONOMIA Y DOCUMENTACIONKeywordsThesaurusLibrary and Information SciencesBibliometricsSurvival analysis050905 science studiesInformation scienceBibliometricsSociology0509 other social sciences050904 information & library sciencesMATEMATICA APLICADAInformation Systems
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.

2011

Clinical outcomes of recurrent hepatitis C virus after liver transplantation are difficult to predict. We evaluated collagen proportionate area (CPA), a quantitative histological index, at 1 year with respect to the first episode of clinical decompensation. Patients with biopsies at 1 year after liver transplantation were evaluated by Ishak stage/grade, and biopsy samples stained with Sirius red for digital image analysis were evaluated for CPA. Cox regression was used to evaluate variables associated with first appearance of clinical decompensation. Receiver operating characteristic (ROC) curves were also used. A total of 135 patients with median follow-up of 76 months were evaluated. At 1…

Liver CirrhosisMaleCirrhosisTime FactorsPortal venous pressuremedicine.medical_treatmentBiopsyKaplan-Meier EstimateLiver transplantationmedicine.disease_causeGastroenterologyRecurrenceRisk FactorsLondonChildFirst episodemedicine.diagnostic_testMiddle AgedHepatitis CLiverFemaleCollagenAdultmedicine.medical_specialtyAdolescentHepatitis C virusHepatic VeinsRisk AssessmentSensitivity and SpecificityEnd Stage Liver DiseaseYoung AdultPredictive Value of TestsInternal medicineBiopsyImage Interpretation Computer-AssistedmedicineHumansDecompensationAgedProportional Hazards ModelsRetrospective StudiesTransplantationHepatologybusiness.industrymedicine.diseaseSurgeryLiver TransplantationTransplantationROC CurveSurgerybusinessVenous PressureLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
researchProduct

Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological re…

2017

Background Few studies examined the outcome of patients with hepatitis C virus (HCV)-related cirrhosis who developed hepatocellular carcinoma (HCC). The relative weight as determinant of death for cancer vs end-stage liver disease (ESLD) and the benefit of HCV eradication remain undefined. This multicentre, retrospective analysis evaluates overall survival (OS), rate of decompensation and tumour recurrence in compensated HCC patients treated with interferon (IFN) according to HCV status since HCC diagnosis. Methods Two groups of patients with HCV-related cirrhosis and HCC were followed since HCC diagnosis: (i) compensated cirrhotics with prior sustained virological response (SVR) on IFN-bas…

Liver CirrhosisMaleCirrhosisTime FactorsSustained Virologic ResponseHepacivirusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyLiver disease0302 clinical medicineRisk Factorshepatitis C viruLiver Neoplasmsvirus diseasesHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CTreatment OutcomeItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDrug Therapy CombinationFemalesustained virological responseLiver cancermedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virussurvivalAntiviral Agents03 medical and health sciencesInternal medicineRibavirinmedicinehepatitis C virus; hepatocellular carcinoma; interferon; survival; sustained virological response; HepatologyHumansDecompensationPropensity ScoreAgedProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryHepatologymedicine.diseasedigestive system diseasesMultivariate AnalysisInterferonsNeoplasm Recurrence LocalbusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

2018

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly…

Liver CirrhosisMaleTime FactorsCirrhosisKaplan-Meier Estimatelaw.inventionascites0302 clinical medicineHepatorenal syndromeRandomized controlled trialFurosemidelawAscitesClinical endpointParacentesisDiureticsalbumin decompensated cirrhosiMineralocorticoid Receptor AntagonistsSettore MED/12 - GastroenterologiaMedicine (all)Hazard ratioGeneral MedicineMiddle AgedSurvival RateCirrhosis030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyQuality-Adjusted Life Yearsmedicine.symptomHyponatremiamedicine.medical_specialty03 medical and health sciencesAlbuminsInternal medicinemedicineHumansSurvival ratealbuminAgedbusiness.industrycirrhosis; albumin; ascitesmedicine.diseaseClinical trialalbumin cirrhosis ascites liver decompensationQuality of LifeHyperkalemiabusinessEsophagus Varices Portal Hypertension Varicosis
researchProduct

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies

2020

INTRODUCTION: Despite the negative impact of covert hepatic encephalopathy on the outcome of patients with liver cirrhosis, data regarding the ability of different testing strategies to predict overt hepatic encephalopathy (OHE) development and mortality are limited. This study aimed to compare the ability of Psychometric Hepatic Encephalopathy Score (PHES), critical flicker frequency (CFF), simplified animal naming test (S-ANT1), and clinical covert hepatic encephalopathy (CCHE) score to predict OHE development and mortality. METHODS: A total of 224 patients with liver cirrhosis were tested with different testing strategies and prospectively followed up regarding clinically relevant outcom…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPsychometricsmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationRisk AssessmentSeverity of Illness IndexArticleEnd Stage Liver Disease03 medical and health sciencesLiver disease0302 clinical medicinePredictive Value of TestsInternal medicineSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyHepatic encephalopathyAgedReceiver operating characteristicbusiness.industryGastroenterologyMiddle Agedmedicine.diseasePrognosisLiverROC Curve030220 oncology & carcinogenesisPredictive value of testsHepatic EncephalopathyFeasibility Studies030211 gastroenterology & hepatologyFemalebusinessFollow-Up StudiesClinical and Translational Gastroenterology
researchProduct